Increased rates of infection have been reported in patients receiving TNF-α inhibitors, with upper respiratory tract infections, pharyngitis and sinusitis, most commonly reported [16], as well as an increased risk of opportunistic infections [18]. The gene discussed is TNF; the disease is infection.